As the British Columbia government today announced plans to sue opioid companies, the timing for Tetra’s clinical trial for cannabis-derived medicine couldn’t be better.
With Health Canada approval under its belt, the nimble Tetra BioPharma is quickly moving forward with an October-slated clinical trial that, if successful, will help cancer patients reduce dependence on opioids.Clinical data shows the company’s new cannabis-based drug can bring rapid relief and may even be a faster-acting alternative to opioid fentanyl.
Interim CEO and chief scientific officer Dr. Guy Chamberland said it’s important to bring cannabinoid products to market in a way that ensures “physicians who have been hesitant” will feel comfortable recommending it.
“Medical cannabis may help reduce the use of drugs like fentanyl for treating breakthrough and chronic pain,” he said.
He said that what’s missing is “un-refuted scientific data on its safety and effectiveness that will satisfy regulators, professional groups and insurers.“Tetra is in the business of providing that evidence, which would see our drug PPP001 become a complementary prescription therapy. “As a prescription drug with a Drug Identification Number, it will be eligible for insurance coverage, making the cannabis-based medication accessible in pharmacies.Patient recruitment will begin in October and the study will be conducted by Montreal-based Santé Cannabis.For more information on eligibility criteria etc. visit the Sante Cannabis website: www.santecannabis.ca/en/research/cannabis-clinical-trial/ or call 514-419-4131.
Here’s the CEO on BNN.
Copyright Notice ©CannabisFindings.com. 2018. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to CannabisFindings.com with appropriate and specific direction to the original content.